Cortexyme (CRTX) Competitors

Omnicell (NASDAQ:OMCL) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Do analysts prefer OMCL or CRTX?

Omnicell presently has a consensus target price of $44.83, suggesting a potential upside of 56.27%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts plainly believe Omnicell is more favorable than Cortexyme.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cortexyme	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Is OMCL or CRTX more profitable?

Omnicell has a net margin of 1.87% compared to Cortexyme's net margin of 0.00%. Omnicell's return on equity of 4.60% beat Cortexyme's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Omnicell	1.87%	4.60%	2.56%
Cortexyme	N/A	-70.96%	-63.53%

Does the media favor OMCL or CRTX?

In the previous week, Omnicell had 2 more articles in the media than Cortexyme. MarketBeat recorded 3 mentions for Omnicell and 1 mentions for Cortexyme. Omnicell's average media sentiment score of 0.63 beat Cortexyme's score of 0.00 indicating that Omnicell is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Omnicell	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cortexyme	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has higher earnings and valuation, OMCL or CRTX?

Omnicell has higher revenue and earnings than Cortexyme. Cortexyme is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Omnicell	$1.11B	1.21	$12.53M	$0.46	62.37
Cortexyme	N/A	N/A	-$89.94M	-$2.97	-0.61

Do institutionals and insiders hold more shares of OMCL or CRTX?

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 63.2% of Cortexyme shares are owned by institutional investors. 2.5% of Omnicell shares are owned by insiders. Comparatively, 27.9% of Cortexyme shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has more volatility and risk, OMCL or CRTX?

Omnicell has a beta of 0.76, indicating that its stock price is 24% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500.

Summary

Omnicell beats Cortexyme on 13 of the 15 factors compared between the two stocks.